A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel

Acta Haematologica

Volumn 134, Issue , 2015, Pages 170-176

  Rinott, Nadav ^c   Mashiach, Tatiana ^a   Horowitz, Netanel A ^a,c   Schliamser, Liliana ^b   Sarig, Galit ^a,c   Keren Politansky, Anat ^a   Dann, Eldad J ^a,c  

^a Rambam Health Care Campus Blood Bank and Apheresis Unit Department of Hematology and Bone Marrow Transplantation   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Idiopathic thrombotic thrombocytopenic purpura; Rituximab; Therapeutic plasma exchange

Indexed keywords

PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; ISRAEL; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; ISRAEL; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929688265     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000371867     Document Type: Article

References (22)

1. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN: The incidence of thrombotic thrombocytopenic purpura-he-molytic uremic syndrome: all patients, idio-pathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3:1432-1436.
2. George JN: Corticosteroids and rituximab as adjunctive treatments for thrombotic throm-bocytopenic purpura. Am J Hematol 2012; 87(suppl 1):S88-S91.
3. Moatti-Cohen M, Garrec C, Wolf M, Bois-seau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A: Unexpected frequency of Up-shaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpu-ra. Blood 2012; 119:5888-5897.
4. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45:139-159.
5. Rock GA, Shumak KH, Buskard NA, Blanch-ette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombo-cytopenic purpura: Canadian Apheresis Study Group. N Engl J Med 1991; 325:393-397.
6. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE: ADAMTS13 activity in thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68.
7. Scully M, Goodship T: How I treat thrombot-ic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164:759-766.
8. Crawley JT, Scully MA: Thrombotic throm-bocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematol Am Soc Hematol Educ Program 2013; 2013:292-299.
9. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M: Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11: 481-490.
10. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, Schwarzinger M, Gal-icier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Chouk-roun G, Presne C, Pourrat J, Hamidou M, Coppo P: Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a subopti-mal response to plasma exchange: experience of the French Thrombotic Microangiopa-thies Reference Center. Crit Care Med 2012; 40: 104-111.
11. Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, Winters JL: Thrombotic thrombocytopenic pur-pura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29:148-167.
12. Schwartz J, Eldor A, Szold A: Laparoscopic splenectomy in patients with refractory or relapsing thrombotic thrombocytopenic pur-pura. Arch Surg 2001; 136:1236-1239.
13. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN: Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500-1511.
14. Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Gal-icier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P: Splenectomy and/or cyclophospha-mide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52:2436-2444.
15. Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, Cambridge G: Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol 2015; 179:414-425.
16. Sadler JE: Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11-18.
17. Fakhouri F, Vernant J P, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grunfeld JP: Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-defi-cient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106:1932-1937.
18. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ: Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451-461.
19. Chemnitz JM, Uener J, Hallek M, Scheid C: Long-term follow-up of idiopathic thrombot-ic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010; 89:1029-1033.
20. Foley SR, Rock G, Barth D, Arnold DM, We-bert KE, Yenson PR, Kelton JG, Clark WF, Li L: A phase II study evaluating the efficacy of ritux-imab in the management of patients with relapsed or refractory TTP. Blood 2014; 124: 4191.
21. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ: A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746-1753.
22. Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Ben-hamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Vey-radier A, Coppo P: Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocyto-penic purpura. Blood 2014; 124:204-210.